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Ovarian cancer is one of the leading causes of cancer-related death among women. Resistance to the disease occurs in more
than 70% of the cases even after treated with chemotherapy agents such as paclitaxel- and platinum-based agents. The immune
system is increasingly becoming a target for intense research in order to study the host’s immune response against ovarian cancer.
T cell populations, including NK T cells and Tregs, and cytokines have been associated with disease outcome, indicating their
increasing clinical signiﬁcance, having been associated with prognosis and as markers of disease progress, respectively. Harnessing
the immune system capacity in order to induce antitumor response remains a major challenge. This paper examines the recent
developments in our understanding of the mechanisms of development of the immune response in ovarian cancer as well as its
prognostic signiﬁcance and the existing experience in clinical studies.
1.Introduction
Cancer is one of the leading causes of death in the developed
world outnumbering even heart disease in the United States
[1]. In turn, ovarian cancer remains the leading cause of
death among gynaecological malignancies and is the fourth
most common cause of cancer-related death among women.
Epithelial ovarian cancer is the main type of the disease
accounting for more than 90% of all malignant ovarian
tumors. According to the initial FIGO stage, the prognosis
of ovarian cancer varies; a 5-year survival reaches 90% when
thedisease is conﬁned within the ovary, butit drops tobelow
50% for the cases that cancer has spread outside the pelvis.
Ovarian cancer is usually diagnosed in advanced stages
(FIGO stages III and IV), and prognosis is generally rather
poor. Major established prognostic factors, apart from FIGO
stage of the disease, includetumor grade, histologic subtype,
and the volume of disease remaining after cytoreductive
surgery [2]. Nevertheless, the value of these factors in
a population with advanced stage and usually high-grade
tumors is limited.
Current treatment of advanced ovarian carcinoma
includes debulking and chemotherapy, mainly the combi-
nation of the use of paclitaxel and platinum agents and at
least 70% of the patients treated with the above combination
initially respond to treatment. Intraperitoneal drug admin-
istration has substantially improved the survival of patients
who have minimal gross disease remaining after surgery and
can also tolerate the side eﬀects of aggressive treatment [3].
Despite the signiﬁcant advances in surgery and chemo-
therapy, the disease is more likely to relapse in about 70% of
the cases [4] with resistance being prevalent in most cases.
As a result, new ways of treating the disease are currently
being explored focusing on the biology of cancer and more
speciﬁcally within the ovarian tumor microenvironment.
Therefore, clinical research has focused on molecular mark-
ers, which are related eithertothe behaviour of thedisease or
theresponse tochemotherapyin ordertodeﬁnetheoutcome2 Clinical and Developmental Immunology
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Figure 1: VEGF exerts its signalling eﬀect via its receptor VEGFR.
VEGF, mainly the VGEFA isoform exerts its eﬀects via binding its
receptor VEGFR (mainly VEGFR2). It is a powerful angiogenic
factor that holds a pivotal role in tumor progress and metastasis.
Itcomprisesanattractivetarget forpossibleagentsthatwillblockits
function and therefore enhance patients’ survival. ID: Intracellular
domain,ED: extracellular domain, TD: Transmembrane domain.
in these patients and establish furthermore potential targets
for therapy.
Oncogenesis inall typesofcancer, includingovarian can-
cer, is a process that involves multiple molecular pathways,
which regulate important functions of cancer cells. In 2004,
the Baltimore group proposed a model for the division of
epithelial ovarian tumors into two rather broad categories
termed type I and type II, that correspond to two main
pathways of tumorigenesis [5].
Themajorgroupsaregenesinvolvedinapoptosisandcell
cycleregulation, genesencodingfor growthfactors andgenes
involvedinangiogenesis.Theprognosticandpredictivevalue
of several factors implicated, in these pathways, has been
recentlystudied.Genetic alterationsin associated genes,such
as mutations of p53, malfunctioning genes of the BRCA
family (BRCA1 and BRCA2) in about 15% of inherited types
ofovariancancer[6],malfunctionoftumorsuppressorgenes
such as ARHI [7], the cyclinE/CDK2 and cyclinD/CDK4
complexes and the cell cycle regulators p27, p15, and p16
have all been studied in this context [8–11]. Although some
studies have reported relevant associations, the prognostic
role of these factors remains to be elucidated in full.
Angiogenesis is a critical function for the expansion of
a tumor and also for its metastatic potential, and it is inﬂu-
enced by the tumor microenvironment [12]. Its signiﬁcance
in ovarian cancer has been well established, and a number
of angiogenic factors have been identiﬁed. The vascular
endothelial growth factor (VEGF) holds a pivotal role in the
angiogenic process [13]. It is produced by cancer cells and
assists tumor progression and metastasis (Figure 1)e x e r t i n g
a central role in the formation of ascitic ﬂuid and metastasis
in the peritoneum. It is also related to the invasive and
metastatic potential of ovarian cancer [14–16].
Immune surveillance has long been recognized as an
importantelementofhostanticancerresponse. Agentswhich
augment immune response as well as antibodies against
certain tumorantigenshave beenapprovedforthe treatment
of diﬀerent types of neoplasms. In the recent years, we have
witnessed important developments in our understanding of
cancer immunology. Many of these developments involve
ovarian cancer, and this paper will focus on them.
2.Cancerand the Immune System
The immune system responds to the presence of cancer anti-
gens. A key advance in recent advances in immunology has
been the elucidation of antigen-speciﬁc cell recognition and
destruction of target cells. Mutations can occur in common
antigens that are found in otherwise normal functioning
genes in the cell; these were initially termed the tumor-
speciﬁc antigens [17], and on those that can be found in
both normal and cancer cells called the tumor-associated
antigens (TAA) [18]. This terminology is still extensively
used but it has been termed as imperfect by researchers and
although still present in the literature, other modern antigen
classiﬁcationshaveemergedbasedontheantigens’molecular
structure and source. More modern terminology divides
antigens into categories such as diﬀerentiation antigens
and overexpression antigens [19] and also viral antigens.
A distinct example of the latter category is Epstein-Barr
Virus Nuclear Antigen (EBNA-1), which is associated with
Burkitt’s lymphoma and nasopharyngeal carcinoma [20].
Identifying tumorantigenshasbeenanongoingprocesswith
a number of techniques, having been employed, based on
several components of the immune system [21–24].
In contrast to early theories that a tumor could not
elicit an immune reaction, later experiments showed that
it actually does provoke the onset of an immune response
[25–27]. More speciﬁc studies have shown that both the
innate and adaptive “arms” of the immune system are impli-
cated in antitumor response [28, 29]. There is a number of
componentsoftheimmunesystemthathavebeenimplicated
with cancer cell elimination, equilibrium, and also escape
from immune surveillance; all three comprising what is
called “immunoediting” [30], a process that emphasizes in
the dynamic interaction of the immune system with cancer,
and it is present in almost all types of tumor including
ovarian cancer. It is a process that has been reinforced in the
last fewyearsforitsusageincancerprogress. Immunoediting
is divided in elimination, equilibrium, and escape. At ﬁrst,
cancer is eliminated, rendered nondetectable, followed byClinical and Developmental Immunology 3
a period of being kept in check by the immune system,
and ﬁnally cancer becomes clinically detectable when it
has escaped antitumor immunity. Thus the immune system
protects the host from cancer and it also plays a role
in “sculpting” immunogenicity, and this has actually been
experimentally shown [31].
Elimination and equilibrium are achieved via lympho-
cytes, mainly the T cell subpopulation [32]. In cancer
patients the “healthy” response against the tumor is counter-
acted by a suppressive, tumor-driven eﬀect. This hypothesis
is strengthened by recent studies showing that the absence or
presence ofT cellsin colorectalcancer specimens more accu-
rately predicted the outcome than using standard prognostic
factors [33].Otherstudiesindiﬀerenttypesoftumor,mainly
cervical and breast cancer, have also shown similar results
[34, 35]. These studies further conﬁrmed the importance
of the immune response in prognosis alongside other more
established factors. Recent studies also support the case of
immunoediting by observing that tumor inﬁltration by lym-
phocytes is linked to tumor-associated immune response,
mainly showing that the presence of tumor inﬁltrating
lymphocytes may be associated with improved prognosis
and clinical outcome in cancer patients [36–38] including
ovarian carcinoma [39, 40]. These observations as well as
preclinical data also suggest that by enhancing the host
immune system, it may achieve tumor destruction and act
synergistically with other anticancer therapies.
Although the development of antitumor immune
response has been well established, there is also evidencethat
tumors can escape destruction by suppressing the immune
system both within the cancer microenvironment and also
on a systemic basis. T regulatory cells (Tregs), for example,
that can suppress eﬀector T cells action have been found in
the microenvironment of several types of tumor [41–43].
Similar eﬀects on regulation of Tregs can also be brought
about in systemic modes of immunosuppression by tumors.
For example, an increase in blood Tregs content has been
observed in melanoma [44]. In colorectal cancer, increased
numbers of activated granulocytes [45] have also been
reported. Such cell types have shown to suppress tumor-
speciﬁc T cells in mouse models [46]. Other types of im-
munosuppression consist of the downregulation of Major
Histocompatibily Complex (MHC) and tumor antigen loss
[47]. They also include disruption of speciﬁc Natural
Killer (NK) cells employment that inhibit immune system-
mediated tumor destruction [41, 48].
3.OvarianCancerand Lymphocyte Response
Epithelial ovarian cancer is characterized by periods of
remission and relapse of sequentially shortening duration
until chemoresistance occurs [40]. Such patients are the best
candidates for immunological studies, since T cells’ presence
can be utilized as markers for disease progress and can be
evaluated at diﬀerent stages of the disease. The progression
of cancer in the peritoneal cavity and the frequent formation
of ascites, which characterize advanced stages of ovarian
cancer, mainly stage IV, make this tumor a model for the
study of diﬀerent lymphocytic populations. Ascitic ﬂuid as
well as peritoneal metastases can be easily obtained through
paracentesis, laparoscopy, or open surgery, and cells can be
screened by various techniques such as ﬂow cytometry or
immunohistochemistry.
It is believedthat the presence or absence of speciﬁc pop-
ulations of T cells, which hold a central role in immunoedit-
ing within epithelial ovarian cancer tumors, is associated
with important diﬀerences in prognosis. Studies in paraﬃn-
embedded tissues have reinforced this notion and have
shown that the presence of tumor inﬁltrating lymphocytes
(TIL) such as CD3+ cells and increased number of cytotoxic
CD8 lymphocytes were associated with prolongation of
survival [49–51]. For example, in the case of CD3 TILs,
Tomˇ sov´ a et al. have shown that patients exhibiting higher
C D 3c e l ln u m b e r sh a da ni m p r o v e do v e r a l ls u r v i v a lo f6 0
months over 29 months for patients that had lower CD3 cell
numbers.
Elimination is also conferred by CD3+ CD56+ cells,
containing theNK-likeT cytotoxiccellswhich havecytotoxic
properties against tumor cells and contain the highest
such property among eﬀector killer cells in vitro [52, 53].
Experiments, using blood cells from lymphoma patients,
showed signiﬁcant expansion of this cell population in ex
vivo conditions, which accounted for the 20% of a cytokine-
induced population that resulted in signiﬁcant cytotoxicity
against cancer cells in vitro [54]. Frozen tissue has also
been used in immunohistochemical studies showing similar
results [55], where the presence of CD3+ cells was shown in
most cancer specimens. In this paper, immunohistochemical
studies also showed the presence of CD4+ and CD8+ TILs
with numbers that were closelyrelated. Moreover, both types
of cells, CD4+ and CD8+, were both present or absent
in specimens examined. The 5-year progress-free survival
percentage for patients with the presence of TILs according
to Zhang et al. was 38%. Nesbeth et al. have recently shown
t h ep o s i t i v ee ﬀect of CD4+ T cells in ovarian cancer via the
use of a novel mechanism that recruits dendritic cells to the
tumor site that in turn activate tumor-speciﬁc CD8+ cells
which then mediate long-term protection [56].
The presence of CD3+ CD56+ cells in ascitic ﬂuid taken
from advanced ovarian cancer patients has been shown to be
inversely correlated with the presence of vascular endothelial
growth factor (VEGF) [57]. In addition, low CD3+ CD56+
content was correlated with poor prognosis and platinum
resistance. NK cells’ rapid activation, and cytotoxic activity
without need for prior sensitization and the release of
cytokines such as IFN-γ,T N F - α, and IL-10, indicates their
importance [58]. Early studies have shown the eﬃcacy of
NK cells against tumors when activated by cytokines [59, 60]
or when ex vivo stimulated lymphokine-activated killer cells
were adoptively transferred into patients [61, 62]. Recent
studies though have shown that the expression of mucin
(MUC)moleculesonthe ovarian cancercell surface, namely,
MUC16whichisacarrierfortheCA125tumormarker,assist
in the avoidance of the tumor cells’ recognition by NK cells
[63]. Human Leukocyte Antigen (HLA) class I antigens that
canplayanegativeroleinantitumorfunctionalityofNKcells
aredownregulatedinovariancancer,hencemakingtheuseof
NKcells possibly quiteimportant in ovarian carcinoma [64].4 Clinical and Developmental Immunology
This is enhanced by ﬁndings that the formation of ascites in
late stage ovarian cancer may be inhibited by Cd-1-mediated
activation of NK cells [65].
Another factor, termed programmed cell death 1 (PD-
L1) which is expressed on tumor cells, has been shown to act
as a prognostic factor. Its expression level has been shown to
be inversely correlated with CD8+ cell count rendering this
proteinafactorofpoorprognosis, sinceithasbeensuggested
to directly inhibit CD8+ cells [66].
Dendritic cells migrate in a transendothelial manner via
the use of L1 IgCaM molecule as has been recently shown by
Maddaluno et al. [67], an observation that may play a role
in tumor metastasis. L1 is a glycosylated protein that has
been recently reported to be expressed in 40%–70% of cases
of epithelial ovarian cancer and is associated with poor
prognosis [68].
Incontrasttotheaugmentationofantitumorresponseby
the aforementioned populations, another speciﬁc subset of
T cells has been shown to play a key role in tumor immunity.
T regulatory cells (Tregs) play a key role in peripheral
tolerance. Since tumor-associated antigens (TAA) are self
antigens, they are subjected to control by peripheral tol-
erance. Tregs within the CD4+ CD25+ T cell population
are characterized by the expression of the FoxP3+ protein
[69, 70]. Humans bearing tumors show an elevated amount
ofTregs in theirbloodaswell asmalignant eﬀusions[71,72].
Sato et al. [69] identiﬁed cells in ovarian tumors expressing
both CD25 and FoxP3. Recently, the presence of Tregs in
ovarian cancer ascites in comparison to normal ascites
has been shown [72]. The presence of Tregs in ovarian
tumors has been associated with reduced overall survival
[73, 74]. More speciﬁcally, Curiel et al. showed for the
ﬁrst time that CD4+ CD25+ FoxP3+ Treg cells correspond
to poor clinical outcome in epithelial ovarian cancer. The
same study also showed that CD4+ CD25+ CD3+ cell
populations were much more concentrated in malignant
ascites rather than nonmalignant ones and in blood. It was
also shown that CD4+ CD25+ cells were preferentially
concentrated in tumor mass rather than in tumor draining
lymph nodes. Furthermore, the presence of FoxP3 alone
was an independent prognostic factor for progress-free and
overall survival.
Therefore, Tregs depletion can be expected to lead to
more eﬃcient treatment and better prognosis. Current ther-
apeutic agents may be useful in this respect. Classical cyto-
toxics, such as cyclophosphamide [75]a sw e l la sa n t i b o d y -
based immunotherapy with Trastuzumab have been shown
to result in a substantial decrease in the number of Tregs
in cancer patients [76]. A recent study has shown selec-
tive accumulation of NK-T cells, activated CD4 and CD8
lymphocytes and also Tregs in ascites formed in ovarian
cancer [72], which complements previous evidence that
tumor-associated lymphocytes are indeed present in ascites
[70, 73, 77] and may be important for the immune response
against the tumor. These results indicate that the presence of
cancer cells can activate lymphocytes and could also result
in a parallel accumulation of Tregs that may inhibit CD8-
mediated immune response against the tumor as has been
suggested before [71, 78]. Recent studies also indicate that
in the case of epithelial ovarian cancer, local treatment with
interleukin 2 may play a role in converting Tregs into Th17
cells, a new player in the ﬁeld of cancer immunotherapy,
with a concomitant relief of Treg-mediated immune sup-
pression and enhancement of antitumor immunity [79, 80].
Plasmacytoid dendritic cells (PDc) have also been shown
to contribute to immunosuppression in ovarian cancer by
inducing tumor microenvironment Tregs [81].
Another type of cells of the immune system, namely
macrophages, are also found in ovarian cancer [82, 83].
The presence of macrophages in tumors has been associated
with tumor growth and metastasis in rodents [84, 85].
Kryczek et al. [83] have shown that the B7-H4+ receptor
expression, which is a negative T cell regulator on tumor-
associated macrophages, in ovarian cancer, induces sup-
pression of T cells encompassing tumor-associated antigens
immunity.
Finally, since the increased concentration of autoanti-
bodiescaninducetheproductionofTregsandclinicalstudies
have reported autoimmune paraneoplastic syndromes (dif-
ferent from autoimmune diseases) [86, 87], there may be
links between cancer and autoimmune disease that remain
to be elucidated in full. These studies may provide us with
a greater insight into Tregs activity and association with
ovarian cancer.
Lately, diﬀerent populations such as vascular lympho-
cyteshaveshown the abilityto formfunctional bloodvessels,
and they may be proven to be an important target for
blocking cancer progression [88].
The identiﬁcation of important subsets of lymphocytes
intumorsandascitesfromovariancancerhasledtothestudy
of possible immunomodulatory eﬀects of current therapies.
Chemotherapy, in particular paclitaxel, may have a positive
eﬀect on the immune response by directly downregulating
Tregs [89]. Tregs can also be suppressed by cyclophos-
phamide as has been exhibited in mouse models [75, 90],
and NK cells can be activated at the same time. The use
of gemcitabine, which is a nucleoside analog, reduced the
number of myeloid suppressor T cells, without reducing
cytotoxic cells such as NK cells [91]. Gemcitabine, in
association with oxaliplatin and interleukins such as IL-
2 and GM-CSF, can have a suppressive eﬀect on Tregs
[92, 93]: therefore, it could possibly have a positive eﬀect on
reducing drug resistance and inﬂuence prognosis and disease
outcome.
4.Cytokines,GrowthFactorsand Association
withLymphocytes’ Mobilityand Response
The composition of lymphocytic populations in blood,
ascites and tumors is regulated by various cytokines and
chemokines produced by the tumors or the components of
the immune system. A simple schematic representation of
these interactions is depicted in Figure 2.
A number of cytokineshavebeen associated with a direct
eﬀect on tumor cells, via surface receptors such as Toll-like
receptors [94], but mainly they have been attributed roles in
assisting the immune response of the body against tumors.
Host antitumor response results from the balance betweenClinical and Developmental Immunology 5
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Figure2:Schematicrepresentationofcharacteristicimmunecells,growthfactors,andcytokinesinteractionsincancer.Interactionsbetween
growth factors such as VEGF, cytokines (e.g., TNFα) and T cells (e.g., NK, Tregs) are shown in this diagram. Tumor cells bring about the
production ofcytokines that assistin the mobilizationofT cells andinduce the production offurther cytokines, and they alsoutilize growth
factors such as VEGF to promote neovasculirisation implicated in metastasis. ↑ means increase where ↓ means decrease.
the T helper 1 (Th1) response, which potentiates immune
response and the T helper 2 (Th2) response with a shift
in favor of the latter characterising oncogenesis and disease
progression. BothTh1andTh2 immuneresponseshavebeen
associated with the production of cytokines such as Inter-
leukin 12 (IL-12), Interleukin 4 (IL-4), Interferon gamma
(IFN-γ), Tumor Necrosis Factor (TNF-α) (Th1 response),
and IL-10 (Th2 response) [16, 95–97]. These cytokines
can also be produced by cancer cells; they are present in
ascites and have been associated with prognosis in ovarian
cancer [71, 98–100]. Gradients between blood and ascites
may play a role in migration of leukocytes [101]a n d
factors that facilitate such movements may include L1 [67].
As a consequence, diﬀerent lymphocytic populations are
involved in the two types of response: for example, CD3+
CD56+ cells are associated with Th1 whereas CD4+ CD25+
cells are associated with Th2 response.
The prognostic role of various cytokines has been
studied, but no absolutely ﬁrm conclusions can be drawn so
far. It is conceivable that cytokines involved in Th1 response
are expected to predict for better prognosis, while the
opposite is expected in those associated with Th2 response.
Interleukinsinthatrespect havereceivedmuch attention.IL-
2initiatestheactivationofTandNKcellsandisalsoessential
forthemaintenanceofself-tolerance throughgenerationand
maintenance of Tregs [102] or by activation-induced cell
death [103] to eliminate self reactive T cells. Cytokines such
as IL-12 [104]a n dI L - 2 1[ 105] are currently considered for
their therapeutic potential in other types of cancer and may
h a v et h es a m ee ﬀect in ovarian cancer. In glioma, in the
case of IL-12, the cytokine is fused with normal glioma cells
and dendritic cells and administered to malignant glioma
patients [104]. IL-12 is associated with favorable prognosis,
and in this study, four patients exhibited a glioma reduction
of 50%. For IL-21, Dou et al. have shown that when the gene
expressing IL-21 is administered in rodents, it has a positive
antitumor eﬀect in squamous cell carcinoma, and therefore
IL-21 may be associated with favorable prognosis. This has
further been enhanced by a recent study showing that the
antitumor eﬀect is increased by human ovarian cancer cells
secreting IL21 alone or in combination with GM-CSF [105].
TNFα may also be associated with prognosis [72, 106, 107],
but reports on whether it is a signature of poor or better
prognosis vary. IL-6 levels have been shown to be increased
in ovarian cancer patients’ serum [108, 109], and it was
correlated with poor overall survival. Another cytokine that
was shown to be associated with the growth of cancer cells
and tumor proliferation is IL-1 [110, 111]. IL-15 has also6 Clinical and Developmental Immunology
been recently shown to activate CD8+ and NKT cells that
may inhibit tumor growth [112]. Further functional studies
are necessary to conﬁrm the above results.
Acytokinethatseemstobeheavilyinvolvedintumorim-
munosuppression is transforming growth factor beta (TGF-
β), a protein that aﬀects proliferation, activation, and diﬀer-
entiation of immune cells and inhibits antitumor immune
response [113]. In cancer cells, the production of TGF-β is
increased, which in turn increases the proteolytic activity
of cells and the binding to cell adhesion molecules in the
extracellular matrix. TGF-β can also convert eﬀector T cells
intoTregs[114].Ithasbeenreportedthatitcanalsopromote
angiogenesis and that process can be blocked by anti-TGF-β
antibodies [115].
TNFα is produced by tumor cells and can induce
autocrine proliferation and disease progression in ovarian
cancer [107, 116, 117]. The autocrine action of TNFα may
have direct eﬀects on tumor cell spread via acting on the
chemokine receptor CXCR4 and also stimulation of blood
vessel formation in the peritoneal tumor by inducing expres-
sion of VEGF and CXCL12 [118]. In contrast, TNFα levels
have also been inversely correlated with the presence of
CD4+ CD25+ cells, and have been shown to directly down-
regulate Tregs [119]. This might indicate a favorable eﬀect of
this cytokine on prognosis and underlines the complexity of
the functions that each of these factors may possess.
A family of proteins called chemokines (CC) may also be
inﬂuencing cellular composition in biological ﬂuids. Recent
studies have exhibited the detection of mRNA for CCL2,
CCL3, CCL4, and CCL5 in solid ovarian tumors by in situ
hybridization [120]. Moreover, CCL5 has been shown to be
secreted by CD4+ T cells, recruits CCR5+ dendritic cells
to the tumor location, and activates them through CD40-
CD40L interactions [56]. The newly matured dendritic cells
prime tumor-speciﬁc CD8+ cells thus providing with long
term protection.
In the protein-rich ascitic ﬂuid, diﬀerent chemokine
moleculeshavebeenshowntobeexpressed,withCCL2being
thepredominantone[121].Inaddition,chemokinestromal-
derived factor-1 (CXCL-1) induced the migration of plas-
macytoid dendritic cells into the tumor microenvironment
in cases of ovarian cancer and induced delivery of survival
signalstoPDC.Inturn,thetumormicroenvironmental PDC
induced IL-10 expressing Tregs [122], which is correlated to
poor prognosis and shorter progress-free survival. Tregs, and
IL-10 are associated with poor prognosis in many types of
cancer. In the case of Tregs it has been exhibited that CCL22
playsacentralroleininducinginﬂuxofthesecellsintotumor
sites, and it binds CCR4 that is expressed on Treg surface
[123].
Interferon gamma (IFN-γ) plays a stimulatory role for
macrophages turning them from immunosuppressive to im-
munostimulatory cells [124]. It also skewed monocyte dif-
ferentiation from tumor-associated macrophages- (TAM-)
like cells to M1-polarized immunostimulatory macrophages.
Taken together these data show that IFN-γ overcomes TAM-
inducedimmunosuppression by preventingTAM generation
and functions.
Furthermore, cytokines such as interleukin 18 (IL-18)
[125] and stroma derived factor 1 (SDF-1) [126] have been
shown tobecorrelatedwithpoorprognosisinovarian cancer
patients, but further studies are required to fully evaluate
them in the tumor microenvironment and the periphery.
VEGF holds a very important role in the oncogenesis as
wellasprogressionandprognosisinovariancancer[55,127].
Itisselectivelyaccumulatedinascitesandoccursinadvanced
stages of thedisease butnot in ascites from cirrhosis [55, 57].
Up to now, this has been attributed solely to its angiogenic
properties. Recently, it has been suggested that VEGF also
exerts an immunosuppressive eﬀect in cancer, as it was
correlated with low levels of IL12, inhibition of dendritic cell
maturation, low numbers of NK-T cells, and upregulation of
Tregs [58, 59, 128–130]. It can also induce expression of the
T cell cosignaling molecule B7-H1 on myeloid dendritic cells
(MDC). Barnett et al. [15] have reported that the blockage
of B7-H1 improved T cell-mediated immune response and
tumor clearance in an ovarian cancer mouse model. VEGF
exerts its eﬀects via its receptor, VEGFR, mainly VEGFR2
[13, 131]. This type of receptor has the ability of activating
the mTOR protein through the Akt/mTOR pathway [131].
Inactivation of mTOR may lead to downregulation of IL-2,
thus conferring a direct negative eﬀect in T cell proliferation
as well as cancer cell proliferation [132, 133]. Except cancer
cells, the VEGFR2 protein has been recently shown to be
expressed selectively ona subset ofT cells, namely, the CD4+
FoxP3+ Tregs [134]. Since FoxP3high Tregs are associated
with poor prognosis, the expression of VEGFR2 on their
surface may be attributed with a more prominent role in
angiogenesis in the future.
The prognostic signiﬁcance of VEGF in ovarian cancer
has received much attention recently. Several studies have
associated serum or plasma levels of VEGF with prog-
nosis [127, 135, 136] .A s c i t e sV E G Fl e v e l sm a yb em o r e
informative, since it reﬂects the site of the most intense
disease activity. It has been shown that VEGF levels above
1900pg/ml were associated with inferior survival in a series
of 41 patients with advanced ovarian cancer [57, 72]. These
results have been conﬁrmed by a more recent analysis of
a larger series and longer followup (Figures 3(a) and 3(b)
show the updated results). Finally, in recent studies serum
Fas protein (sFas) levels and serum VEGF levels have been
found to be increased in ovarian cancer patients correlated
with a short duration of the relapse-free period [137].
5.Harnessing the Immune System for Cancer
Therapy:A DrivenResponse
In general, there are three approaches to harnessing the
immune system response in order to ﬁght cancer: (1) use
exogenously administered antibodies, (2) elicit a humoral
and a cellularresponse, and (3) explore the activation and/or
generation of antigen-speciﬁc CD4+ and CD8+ cells. The
strategies which are in the more advanced stages of drug
development are the use of monoclonal antibodies and
cytokines. The other strategies will be discussed more brieﬂy.
Antibodies with the potential to be used in cancer
treatment are often targeting either the tumor directly,Clinical and Developmental Immunology 7
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Figure 3: Clinical data concerning patients undertaking chemotherapy. Progression-free survival (a) and overall survival (b) of 54 patients
with advanced ovarian cancer receiving ﬁrst-line, platinum-based chemotherapy, according to VEGF levels in ascites. The lower levels were
associated with signiﬁcantly longer progression-free (P = .0297) and overall (P = .0164). Median followup: 33 months.
the tumor microenvironment, or function as modulators of
immune response [138]. Another way is to target intra-
cellular pathway molecules by the use of cell penetrating
agents [139]. Antibody immunotherapy does not seem to
interfere with suppressor mechanisms that could limit its
treatment capacity. Antibodies usually act by the induction
of death pathways by engaging with receptors on cell surface,
antibody-dependent cellular cytotoxicity (ADCC), and the
blockade of tumor growth factors such as vascular endothe-
lial growth factor (VEGF). There is a growing number of
potential agents, mainly antibodies, currently undergoing
evaluation in clinical trials [140]. Such antibodies include
Trastuzumab [141], Oregovomab [142], Bevacizumab, and
Cetuximab [143, 144]. Published data are shown in Table 1.
VEGF, mainly the VEGF-A isoform, may be the more
promising therapeutic target. It is a powerful angiogenic
molecule that has been associated with tumor progression,
poor prognosis, and drug resistance in ovarian cancer.
In addition, it has immunosuppressive properties, as pre-
viously discussed. Recent data have suggested that an anti-
VEGF monoclonal antibody (Bevacizumab) is eﬃcient in
platinum-resistant disease [145–147, 154]. By combining
paclitaxel and/or carboplatin agents with VEGF inhibitors,
such as bevacizumab, we may overcome resistance to chem-
otherapy. This hypothesis is currently tested in two ran-
domisedstudies[148,149].Bothstudiesshowed asigniﬁcant
PFS prolongation by the administration of Bevacizumab.
Another monoclonal antibody already tested in a phase
III randomized study is oregovomab, which recognizes
an epitope on CA125. The formation of the oregovomab-
CA125complexresultsinthedevelopmentofCA125-speciﬁc
immune response [150]. The development of such response
hasbeenshown topredictimprovedsurvival in asmall phase
II study [151]. In the phase III study, although no survival
advantage was found when it was given as maintenance
after remission following ﬁrst-line chemotherapy, subgroup
analysis showed that patients with low-volume residual
disease (<2cm), Ca125 ≤ 65IU/mL after the 3rd cycle of
chemotherapy, and CA125 ≤ 35IU/mL at entry experienced
a 2-fold increase in median time to progress (TTP) [152].
The IMPACT study is currently evaluating the role of
oregovomab in this subset of patients.
The use of cytokines in cancer therapy has also been
evaluated. Certain cytokines, such as IFNs, can augment
antitumor response andwere consideredas promising agents
in cancer therapy. IFN-α, is approved for the treatment
of malignant melanoma and kidney cancer. It has been
shown that GM-CSF-secreting tumor cell immunotherapy
with VEFG-blocking agents prolonged survival of cancer
bearing mice [155, 156], while IL-2 and GM-CSF can have a
suppressive eﬀectonTregs[92,93].GM-CSFincombination
with recombinant IFN-γ1 and carboplatin in a phase II
trial has been recently shown to have a reasonable response
against recurrentplatinumsensitive ovariancancer[157].All
thesepreclinicaldatasuggestthattheuseofcytokinesmay be
eﬃcacious in ovarian cancer. IFN is the most well-studied
agent. Several randomized studies, based on promising
phase II results, have been published during the last decade8 Clinical and Developmental Immunology
Table 1: Selected clinical studies of monoclonalantibodies used for the treatment of ovarian cancer.
Antibody Mechanism of
action
Representative Phase II studies Phase III studies
Population Treatment Results Population Treatment Results
Bevacizumab
(Genentech/R-
oche)
Binds to VEGF
Antiangiogenic
Immunosuppre-
ssive
Refractory
(n = 32) [145]
Monotherapy
(n = 23) With
chemotherapy
(n = 9)
RR 16%
PFS 5.5m
OS 6.9m
First-line ICON
7[ 146]
Carboplatin/Paclitaxel
versus
Carboplatin/Paclitax-
el/Bevacizum
ab
Median
PFS
17.3m
versus
19m,
P = .0041
10.3m
versus
11.2m
versus
14.1,
P<. 00001
Refractory
(n = 44) [147] Monotherapy
RR 16%
PFS 4.4m
OS 10.7
GOG 218 [148]
Carboplatin/Paclitaxel
versus
Carboplatin/Paclitax-
el/Bevacizum ab
versus
Carboplatin/Paclitax-
el/Bevacizum ab
+ Bevacizumab
maintenance
Oregovomab
(AltaRex Corp)
Binds to CA125
Development of
a humoraland
cellular antitumor
response
2nd line
treatment
(n = 20) [149]
With
chemotherapy
Development
of T cell
response was
associated
with
improved
survival
Maintenance
after ﬁrst-line
(n = 147) [150]
Oregovomab versus
placebo
Median
PFS
13.3m
versus
10.3m,
P = .71
Maintenance
after ﬁrst-line
Residual<2cm,
CA125 < 65
after 3rd cycle,
CA125 < 35 at
entry (n = 354)
Oregovomab versus
placebo Awaited
Trastuzumab
(Genentech)
Binds to HER2
extracellular
domain
Recurrent
(n = 41) [141] Monotherapy RR 7.3% PFS
2m
Pertuzumab
(Genentech)
Inhibitor of HER
dimerization
87% platinum-
resistant
(n = 123) [151]
monotherapy RR 4.3% PFS
6.6w
Cetuximab
(Bristol-Myers
Squibb)
EGFR inhibitor First-line
(n = 41) [152]
Combination
with
paclitaxel/carb-
oplatin
PFS 14.4m
Matuzumab
(Merck/Sero-
no/Takeda)
EGFR inhibitor
Platinum-
resistant
(n = 37) [153]
Monotherapy
RR 16.2m
TTP 54d OS
13.3m
evaluating the role of interferon in addition to ﬁrst-line
therapy or as maintenance strategy. The results of these
studies are summarized in Table 2. The ﬁrst study showed
a PFS but not OS beneﬁt [158]. Nevertheless, the standard
of Cisplatin/Cyclophosphamide, used in that study has been
substituted by Paclitaxel/Carboplatin, and thus these results
are diﬃcult to be viewed in the context of current practice
in ovarian cancer. Two randomized studies using the current
standard showed no beneﬁt from the addition of IFNs in the
treatment of ovarian cancer [159, 160].
Methods to augment an immune response against tumor
antigens have also been explored [161, 162]. The most
studied have been vaccines or macrophage-activated killer
(MAK) cells. Within this context, IFN-γ has recently been
shown to reverse the immunosuppressive properties of
macrophages so its local administration could potentially
increasetheeﬃcacyofantitumorimmunotherapiesbasedon
the generation of eﬀector T cells [163], an observation that
contradicts previous studies mentioned above where IFN-
γ showed no positive eﬀect within the tumor microenvi-
ronment. Tumor antigens, synthetic tumor peptides, whole
tumor cells, tumor cell lysates, or anti-idiotypic antibodies
are among the list of initiators of an immune response
[161]. In some protocols, injection of synthetic peptides in
combination with GM-CSF is performed. In diﬀerent pro-
tocols, dendritic cells (antigen presenting cells) loaded withClinical and Developmental Immunology 9
Table 2: Selected clinical studies of cytokines for the treatment of ovarian cancer.
Cytokine Phase III studies
Population Treatment Results
IFN-γ First line (n = 148) [156] Cisplatin/Cyclophosphamideversus
Cisplatin/Cyclophosphamide/IFNγ
3-year OS
58% versus 74% (P = .23)
3-year PFS
38% versus 51% (P = .031)
IFNa-2a Maintenance after ﬁrst-line (n = 300) [157] IFNa-2a versus
Observation No beneﬁt
IFN-γ First line (n = 847) [158] Carboplatin/Paclitaxel versus
Carboplatin/Paclitaxel/IFN-γ
Median OS
Not estimated versus
1138d
HR: 1.45, P = .001
synthetic peptides, immunocomplexes of tumor-associated
antigens with antibodies [162] through activating Fcγ-R
[163], or fusion of dendritic cells with tumor cells are
utilized.Dendriticcellspresent antigenstoCD4+CD8+cells
while delivering stimulatory signals necessary for eﬀective
T cell activation. They can also directly downregulate an
immune response or induce immune tolerance [164]. Vac-
cines using either gene-modiﬁed dendritic cells or whole
tumor cells have also been explored [163, 165]. Peptide
vaccines have been used so far in a lesser extent since
they have some important limitations [166]. Although the
development of a speciﬁc immune response could be shown
inpatientsundergoingsuch approaches [167,168],theirrole
remains investigational.
The ex vivo expansion of immunologically relevant
autologous populations have also been studied. MAK cells
have been used as a form of adoptive immunotherapy alone
or in combination with monoclonal antibodies [58, 169,
170].MAKcanreach tumorsites byintraperitoneal infusion,
but most studies are small and the role of this approach
remains undetermined. Using speciﬁc CD4+ and CD8+
cells against tumor antigens may provide another way of
ﬁghting cancer. These cells need to be activated against
tumor antigens before being administered to the patient.
Activation can be achieved by either stimulating peripheral
blood mononuclear cells (PBMC) in vitro, or by ex vivo
expansion of TILs [162, 167]. Recently, the adoptive transfer
of T cells expressing chimeric NKG2D receptors can lead to
long-term, tumor-free survival in a murine model ofovarian
cancer [171]. Genetic modiﬁcation of T cells is another
emerging approach but its application in ovarian cancer has
not been successful so far [165].
Agents such as oligodeoxynucleotides containing dinu-
cleotides with unmethylated CpG motifs (CpG-ODN) that
recruit and activate innate eﬀector cells throughout the
abdominal cavity to the tumor site might control tumor cell
growth and ascites formation [172].
Reports for the implication of Tegs in suppression of
antitumor response in cancer development and prognosis
havealready beendiscussed.Therearecurrentlyclinicaltrials
using ONTAK in ovarian cancer patients, with encouraging
results [15, 173]. ONTAK is a fusion toxin that consists
of IL-2 genetically fused to the enzymatically active and
translocating domains of diphtheria toxin. It can deplete
functional Tregs, as shown by Curiel et al. [173]i no v a r i a n
cancer patients (including one patient at stage IV), by 50%
in serum and it is considered to lead to better prognosis.
ONTAK is approved by the FDA to be used in the treatment
of CD4+ CD25+ Treg-mediated tumors.
6.ConclusionandFutureConsiderations
Both the innate and adaptive immune response can be of
great importance in the battle against ovarian cancer.
Throughout this paper, mechanisms of reaction of the
immune system against tumors were highlighted, stressing
the importance of such anti tumor response.
The prognosis of advanced ovarian cancer has been
improved in the recent years. Nevertheless, after the intro-
duction of paclitaxel in ﬁrst-line treatment, no dramatic
advance in progress-free survival of the patients using
cytotoxic chemotherapy can be foreseen in the immediate
future. On the contrary, targeted therapies may hold a sig-
niﬁcant promise, as shown in other neoplasms. The immune
response against the tumor may be a promising target,
especially after much recent data has associated various
elements with prognosis.
The previousdecadewas characterized bymany attempts
to establish interferon as a standard in the treatment of
ovarian cancer. The failure of those attempts stresses the
disease’s complexity. At the moment, monoclonal antibodies
seem to be the most promising agents, currently tested in
phase III trials.
There is still much to clarify regarding the mechanisms
governing the development of host antitumor response in
order to ﬁnd strategies to augment it. The interaction with
other important functions, such as angiogenesis, may imply
that more than one function needs to be blocked for achiev-
ing an eﬃcient therapy. Further progress in basic research
in combination of the awaited results of large randomized
clinical trials will hopefully enrich our armamentarium
against ovarian cancer.
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